Post-dispensing stability surveillance: Stavudine

Abstract

BackgroundStavudine, a thymidine nucleoside, is a reverse transcriptase inhibitor, which is extensively used in the treatment of HIV infected patients. According to the World Health Organization (2006), stavudine must be stored in well closed containers and be protected from light. In addition, the manufacturer recommends that stavudine be stored below 25°C in a tightly closed container. However, because of the stigma associated with the disease condition, patients may attempt to hide their medication by storing the drug in more anonymous packaging, which may not comply with these storage requirements. Furthermore, the high temperature and humidity conditions found in sub-tropical areas such as Durban, KwaZulu-Natal, place additional environmental stress on the drug. Research has shown that stavudine can degrade to thymine under hydrolytic, oxidative and photolytic conditions. Therefore, this study investigated the stability of stavudine in packaging other than that used by the manufacturer and under temperature and humidity conditions that were higher than those recommended by the manufacturer.MethodStavudine capsules were placed in different types of packaging and then subjected to different temperature and humidity conditions. At two week intervals the capsules were analysed using HPLC (high pressure liquid chromatography).ResultsStavudine capsules stored in packaging other than that used by the manufacturer and under temperature and humidity conditions that are higher than those recommended by the manufacturer showed significant degradation.ConclusionPatients taking stavudine stored under sub-optimal conditions may ingest less than the required dose of stavudine. This can lead to drug resistance and treatment failure.

<p>Does Antiretroviral Therapy Packaging Matter? Perceptions and Preferences of Antiretroviral Therapy Packaging for People Living with HIV in Northern Tanzania</p>

“…These innovations should also incorporate designs that would protect the ARTs from high temperature and moisture in order to reap maximum benefit from adherence. 13 These findings should be interpreted in light of the study's limitations. We sought to manage social desirability bias by reassuring participants that their responses would have no impact on their clinical care; however, participants may still have been inclined to respond in a positive manner.…”

“…One challenge associated with the practice of selfrepackaging is that drugs are purposely packaged by manufacturers to optimize medication stability and therapeutic benefits. 7,[11][12][13] For example, packaging provides protection against adverse external conditions, such as light and moisture, which may be particularly important in tropical climates. Packaging also includes printed information intended to assist patients in taking medication as prescribed (eg, instructions about maintaining consistent timing of doses), minimizing side effects (eg, guidance to take with food), expiration dates, and details that may prevent counterfeiting (eg, branding, serial codes).…”

HIV-specific legislation in sub-Saharan Africa: A comprehensive human rights analysis

“…To subject such a person to HIV testing without consent represents an infringement of the right to liberty, security and a fair trial provided for under international human rights law. 118 The violation of these rights is particularly acute in the case of persons who are merely 'apprehended' for sexual offences, as is the case under the HIV law of Uganda. There is no justification, under human rights norms and in terms of public health, for blanket HIV testing of all people living with HIV accused of sexual offences.…”